Explore our certified active ingredients and fine chemicals engineered for cosmetic, pharmaceutical, and industrial manufacturing excellence.
In modern dermatological pharmacology and advanced cosmeceutical formulation development, sourcing Azelaic Acid (CAS 123-99-9) and Metronidazole (CAS 443-48-1) together from a single qualified B2B supplier has become the gold standard for pharmaceutical manufacturers, compounding pharmacies, and contract development and manufacturing organizations (CDMOs). Both active pharmaceutical ingredients (APIs) target overlapping yet distinct mechanistic pathways in inflammatory skin conditions, particularly Papulopustular Rosacea, Erythematotelangiectatic Rosacea, and recalcitrant Acne Vulgaris.
While Azelaic Acid acts primarily as a competitive inhibitor of 5-alpha-reductase, anti-keratinizing agent, and scavenger of reactive oxygen species (ROS), Metronidazole delivers potent anaerobic antibacterial and anti-protozoal activity while downregulating neutrophil-generated hydroxyl radicals. Co-formulating or dual-sourcing these compounds enables formulation scientists to achieve a multi-targeted therapeutic cascade that significantly enhances clinical clearance rates compared to monotherapy.
A naturally occurring saturated dicarboxylic acid ($C_9H_{16}O_4$) that inhibits mitochondrial oxidoreductases and 5-alpha-reductase, normalizes follicular keratinization, reduces Cutibacterium acnes density, and suppresses tyrosinase to prevent post-inflammatory hyperpigmentation (PIH).
A synthetic nitroimidazole derivative ($C_6H_9N_3O_3$) that disrupts microvascular inflammation by reducing extracellular reactive oxygen species (ROS), suppressing neutrophil chemotaxis, and eliminating microbial triggers associated with Demodex folliculorum mites.
Clinical trials demonstrate that combining 15% Azelaic Acid gel with 0.75%–1% Metronidazole cream reduces inflammatory lesion counts by over 78% within 8 weeks, providing faster erythema resolution and superior barrier repair over single-agent regimens.
JIMPOCHEM CO., LTD operates state-of-the-art chemical synthesis facilities, providing scalable volume, guaranteed chemical purity, and continuous regulatory compliance for international pharmaceutical distributors.
Formulating Azelaic Acid and Metronidazole into a single stable emulsion, hydrogel, or microemulsion presents distinct physicochemical challenges due to their differing solubility profiles, crystalline structures, and pKa values. As a premier raw material supplier, JIMPOCHEM offers technical guidance and micronized particle sizing tailored to overcome solubilization hurdles.
Azelaic acid ($pKa_1 = 4.55, pKa_2 = 5.41$) exhibits optimal solubility and skin penetration in slightly acidic environments (pH 4.0 – 5.5). Metronidazole remains highly stable across pH 4.0 – 7.0 but is subject to photodegradation if exposed to UV radiation in aqueous solutions. Co-formulation requires precise buffer systems (e.g., Citric Acid / Sodium Citrate) to prevent recrystallization of Azelaic Acid while protecting Metronidazole from oxidative degradation.
Modern pharmaceutical research focuses on encapsulated dual-delivery systems:
Global pharmaceutical supply chains require absolute continuity, cost competitiveness, and uncompromised regulatory alignment. Sourcing Azelaic Acid and Metronidazole from JIMPOCHEM in China offers multi-faceted supply chain security backed by Shandong Province's massive chemical industrial cluster.
We leverage direct access to key precursors—such as oleic acid oxidation routes for Azelaic Acid and 2-methylimidazole for Metronidazole—ensuring price stability even during global chemical market fluctuations.
Located in the Chemical Industry Park of Jinan City, our 500+ acre facility utilizes automated digital synthesis reactors, real-time crystallization control, and high-volume batch processing to deliver metric-ton scale orders rapidly.
Direct access to Qingdao and Shanghai ports enables rapid containerized ocean freight, air transport for urgent samples, and tailored climate-controlled packaging to preserve API assay stability globally.
Navigating international regulatory frameworks is critical when procuring dual APIs. Azelaic Acid and Metronidazole are categorized under varied regulatory tiers depending on target market geography and clinical intention:
Every batch undergoes stringent analytical validation before dispatch, including High-Performance Liquid Chromatography (HPLC) assay (>99.0%), Gas Chromatography-Mass Spectrometry (GC-MS) for residual solvents, Heavy Metal limits (<10 ppm), and strict bio-burden microbial testing.
Established in 2010 and headquartered in the Chemical Industry Park of Jinan City, Shandong Province, JIMPOCHEM CO., LTD spans over 500 acres. As a professional chemical raw material manufacturer integrating R&D, production, sales, and technical services, we specialize in high-end fine chemicals, active pharmaceutical ingredients, and cosmetic raw materials. Certified under ISO quality management and environmental systems, we serve over 5,000 corporate clients across 200+ countries.
Our core team comprises industry veterans with over a decade of hands-on expertise. We do not merely supply raw materials; we provide end-to-end support in product development, formulation optimization, custom synthesis, and supply chain management to elevate your market competitiveness.
Find detailed answers regarding chemical stability, ordering procedures, documentation, and co-formulation parameters.
Browse our extensive portfolio of specialty chemicals, fluorinated compounds, and pharmaceutical excipients.
JIMPOCHEM